This version of the Guidance has been updated to reflect several key developments as indicated below. Updated references have been provided throughout the Guidance. 

Global Changes Occurring throughout the document:

• RAV changed to RAS
• Standardized renal function parameter from CrCI to eGFR
   

Initial Treatment:

• Includes new recommendation to shorten the duration of ledipasvir (90 mg)/sofosbuvir (400 mg) in patients without cirrhosis to 8 weeks for non-black, HIV-uninfected, and whose HCV RNA is <6 million IU/mL
• Updated grading of sofosbuvir/velpatasvir for genotypes 5 and 6
• Language added related to recent data regarding 8 weeks of PrOD for genotype 1b with early stage fibrosis
   

Retreatment:

• Updated recommendations in Genotype 3 sections
   

Decompensated:

• Extrapolation of data from patients with compensated cirrhosis to patients with decompensated cirrhosis in genotypes 5 and 6
   

Renal:

• Genotype 1 elbasvir/grazoprevir class rating changed from Class II to Class I
   

Upcoming Updates:

• Guidance will be forthcoming regarding treatment of adolescents living with chronic HCV given recent FDA-approvals